Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Are The Current (2025) And Forecast (2029) Sizes Of The Major Depressive Disorder Market?
The market for major depressive disorder has experienced consistent expansion over recent years. Projections indicate its value will increase from $6.12 billion in 2024 to $6.26 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 2.3%. This historical growth is primarily due to advancements in pharmaceuticals, heightened mental health awareness, the availability of psychological therapies, and various public health initiatives.
The market size for major depressive disorder is anticipated to experience consistent expansion in the coming years. It is projected to reach $7.14 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 3.4%. This projected growth during the forecast period stems from factors such as precision medicine, telepsychiatry and teletherapy, innovative treatment approaches, and the worldwide expansion of mental health services. Key developments expected during the forecast period encompass early intervention, peer support and online communities, comprehensive holistic approaches, and resilience and coping strategies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp
Which Industry Drivers Are Expected To Accelerate The Major Depressive Disorder Market From 2025 To 2029?
The major depressive disorder market’s growth is projected to be driven by an uptick in substance and alcohol abuse cases. These terms refer to excessive and detrimental consumption patterns of various substances, including alcohol, which can result in adverse physical, psychological, and social outcomes. Such abuse frequently appears alongside major depressive disorder, with both conditions often exacerbating one another and markedly elevating the potential for physical and mental detriment. As an illustration, a survey released in July 2024 by the Substance Abuse and Mental Health Services Administration, a US-based department of health and human services, reported that in 2023, 3.1% of people (8.9 million) engaged in opioid misuse, and 21.8% of individuals aged 12 or older consumed marijuana, establishing it as the most widely used illicit drug. Furthermore, 9.4% of individuals aged 12 or older reported vaping nicotine in the past month, representing an increase from 8.3% recorded in 2022. Consequently, the escalating number of substance abuse and alcohol abuse cases is propelling the major depressive disorder market’s expansion.
How Is The Major Depressive Disorder Market Classified Into Different Segments?
The major depressive disordermarket covered in this report is segmented –
1) By Treatment: Psychotherapy; Medications; Electroconvulsive Therapy (ECT); Transcranial Magnetic Stimulation (TMS); Other Treatments
2) By Diagnosis: Physical Examinations; Laboratory Tests; Psychiatric Evaluations; Diagnostic And Statistical Manual of Mental Disorders (DSM-5); Other Diagnosis
3) By End-User: Clinics; Hospitals; Other End-Users
Subsegments:
1) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Interpersonal Therapy (IPT); Dialectical Behavior Therapy (DBT); Psychodynamic Therapy
2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs); Monoamine Oxidase Inhibitors (MAOIs); Atypical Antidepressants
3) Electroconvulsive Therapy (ECT): Unilateral ECT; Bilateral ECT; Modified ECT
4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS); Deep Transcranial Magnetic Stimulation (dTMS); Theta Burst Stimulation (TBS); Navigated Brain Stimulation (nTMS)
5) Other: Cognitive Behavioral Therapy (CBT); Psychodynamic Therapy; Interpersonal Therapy (IPT); Vagus Nerve Stimulation (VNS); Ketamine Therapy; Bright Light Therapy; Psychedelic-Assisted Therapy; Medication (Antidepressants)
What Are The Latest Industry Trends Transforming The Major Depressive Disorder Market?
Leading companies within the major depressive disorder market are prioritizing the development and regulatory approval of innovative products to secure a competitive edge. The necessity for enhanced efficacy and safety in major depressive disorder treatments is driving an increase in drug approvals, exemplified by medications like VRAYLAR (cariprazine). Specifically, in December 2022, AbbVie Inc., a US-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency, for VRAYLAR (cariprazine) to serve as an adjunctive therapy alongside antidepressants for treating major depressive disorder (MDD) in adults. VRAYLAR functions as an innovative atypical antipsychotic drug, designed to balance dopamine and serotonin levels within the brain. Notably, it represents the inaugural atypical antipsychotic sanctioned as an adjunctive treatment for major depressive disorder. Furthermore, it is offered in capsule form and is administered once daily.
Which Leading Players Are Enhancing Their Major Depressive Disorder Market Presence Worldwide?
Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report
Which Region Currently Holds The Largest Share Of The Major Depressive Disorder Market?
North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Major Depressive Disorder Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp
Browse Through More Reports Similar to the Global Major Depressive Disorder Market 2025, By The Business Research Company
Mental Health Apps Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/mental-health-apps-global-market-report
Behavioral And Mental Health Software Global Market Report 2025
Residential Substance Abuse And Mental Health Facilities Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model